Search

everythinglearnresearchcommunity

for

Search:↓

Excess sebum rich in cholesterol and triglycerides can lead to hair loss through inflammation, with treatments like Ciclopirox shampoo, Benzoyl Peroxide shampoo, and Clindamycin gel recommended for managing conditions like seborrheic dermatitis and folliculitis. Pioglitazone is suggested for Lichen Planopilaris, while Omega-3s and reducing processed foods may improve sebum quality, though genetic factors play a significant role.

The user reports progress in hair regrowth using topical finasteride/minoxidil, microneedling, topical dutasteride, latanoprost, and MSM supplements. They express frustration over the lack of interaction on progress posts compared to trivial topics.

User shared 13 months of progress using finasteride, microneedling, vitamins, and scalp care, and recently started stemoxydine. The post includes before and after photos.

A user shared a 9-month hair loss treatment update using scalp micropigmentation (SMP), finasteride, minoxidil, derma pen, ketoconazole shampoo, and low-level laser therapy (LLLT), with plans for a hair transplant. Another person suggested increasing the dosage of finasteride and minoxidil and using a derma roller weekly.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

A 32-year-old male is considering options to soften a dense transplanted hairline after experiencing accelerated hair loss and intolerance to finasteride and dutasteride, while using minoxidil. He is exploring partial electrolysis or laser treatments to achieve a natural look with a short buzz cut, avoiding a second transplant or scalp micropigmentation.

A user shared their 7-month progress on hair regrowth using a regimen of dutasteride, minoxidil, stemoxydine, microneedling, and keto shampoo. They noted significant improvement, particularly in vellus hair growth, and discussed the potential addition of RU58841, though they experienced side effects with it previously.

The user experienced significant hair shedding after pausing their hair care regimen, which included finasteride, micro-needling, Nizoral shampoo, vitamin D, essential oils, melatonin, caffeine, exercise, and protein intake. They are concerned if the shedding is due to the break in their routine or a normal phase of finasteride use.

A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.

The user shared progress on hair regrowth using oral dutasteride, oral minoxidil, and verteporfin procedures. They reported some regrowth after 6-9 months of treatment.

User shared 126-day progress using Fin/Min/Niz/Microneedling for hair loss. Others discussed microneedling depth, results timeline, frontal coverage, and switching to Dutasteride.

The user has been treating hair loss with Minoxidil, Finasteride, Derma stamping, Nizoral shampoo, and hair and nail vitamins for two months, experiencing mood swings from Finasteride that stabilized over time. They are seeking opinions on their progress.

OP experienced diffuse thinning for 11 years and used Minoxidil and Finasteride previously. They now use Pyrilutamide 0.5% and Alfatradiol 0.1%, resulting in significantly reduced hair loss.

The user reports that their hair loss treatment with oral minoxidil, dutasteride, finasteride, topical minoxidil, ketoconazole shampoo, and microneedling has plateaued, with no significant additional regrowth. They have stopped using creatine to simplify their regimen and are relieved with the current state compared to before treatment.

The conversation discusses diffuse unpatterned alopecia (DUPA) and its possible causes, including sensitivity to DHT, not being androgenic alopecia, being diffuse alopecia areata, or hormonal issues. Treatments mentioned include topical melatonin, Clobetasol Propionate for alopecia areata, and the lack of results from using finasteride, dutasteride, and minoxidil.

A 34-year-old man with diffuse hair loss experienced regrowth and hair thickening using daily Dutasteride, oral and topical Minoxidil, a specialized shampoo, and microneedling. He switched from Finasteride to Dutasteride after seeing significant improvement in a peer, reporting no side effects.

The user is managing hair loss with oral finasteride, recently switching to dutasteride, and topical minoxidil, but faces challenges due to seborrheic dermatitis. They seek advice on effective regrowth methods that don't worsen their condition, with suggestions including various shampoos like Vichy Dercos and ketoconazole.

The user stabilized hair loss with oral finasteride, dutasteride, and topical minoxidil, and underwent a stem cell and PRP procedure. Recent increased hair shedding may be due to restarting dermarolling, affecting minoxidil absorption, or the waning effects of the stem cell treatment.

User is using minoxidil with tretinoin 0.025% and experiencing peeling and burning on the scalp. They are unsure if it's effective or if they are using it too frequently.

The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

The user resumed using topical finasteride after a two-week break and will update on side effects like water retention and gynecomastia in a month. They are also starting DIM and zinc.

The user is using minoxidil, finasteride, dermarolling, and other treatments for hair regrowth, showing promising results in the temple area. Despite some skepticism, there is optimism about potential improvement.

The user has been using topical 5% Minoxidil, 0.1% Finasteride, dermastamping, 2% ketoconazole, and a DHT-blocking shampoo with saw palmetto, caffeine, biotin, and argan oil for hair loss. Despite some baby hair growth on one side, the user is experiencing continued hairline recession and shedding, leading to distress.

User noticed beard and sideburn hair loss, and thinning eyebrows, diagnosed with alopecia barbae and male pattern baldness, and prescribed Desonide cream. User seeks feedback on Desonide cream.

The conversation provides tips to reduce facial skin side effects from Minoxidil, such as changing pillowcases, sleeping on the back, careful application, hydration, and taking breaks. One reply suggests that alcohol in Minoxidil formulations, not Minoxidil itself, may cause skin aging.

The user experienced initial regrowth with finasteride and minoxidil but is now facing increased hair thinning, possibly due to a second shedding phase. They are considering increasing finasteride dosage or adding dutasteride, despite availability issues, and have started microneedling.

The user is using Dutasteride, Minoxidil, microneedling, RU58841, and tretinoin for hair loss. They are experiencing shedding but notice new hair growth and are curious about the timing of future shedding phases.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.